Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance

Blood

Volumn 100, Issue 10, 2002, Pages 3819-3821

  Pollett, Jonathan B ^a,b   Trudel, Suzanne ^a,b   Stern, Daniel ^a,b   Li, Zhixiong H ^a,b   Keith Stewart, A ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DEXAMETHASONE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; PROTEIN BCL X; STAT3 PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; UPREGULATION;

EID: 0037111779     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0608     Document Type: Article

References (17)

1. Bergsagel PL, Nardini E, Brents L, et al. IgH translocations in multiple myeloma: A nearly universal event that rarely involves c-myc. Curr Top Microbiol Immunol. 1997;224:283-287.
2. Nishida K, Tamura A, Nakazawa N, et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood. 1997;90:526-534.
3. Kuipers J, Vaandrager JW, Weghuis DO, et al. Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Cancer Genet Cytogenet. 1999;109:99-107.
4. Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res. 1998;58:5640-5645.
5. Avet-Loisseau H, Brigaudeau C, Morineau N, et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1999;24:9-15.
6. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, Kuehl WM. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Sci Acad U S A. 1996;93:13931-13936.
7. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16:260-264.
8. Finelli P, Fabris S, Zagano S, et al. Detection of t(4;14) (p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization. Blood. 1999;94:724-732.
9. Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4;14) (p16.3;q32) in multiple myeloma involves fibroblast growth receptor 3 gene. Blood. 1997;90:4062-4070.
10. Intini D, Baldini L, Fabris S, et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol. 2001;114:362-364.
11. Plowright EE, Li Z, Bergsagel PL, et al. Ectopic expression of fibroblast growth factor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood. 2000;95:992-998.
12. Tu Y, Renner S, Xu F, et al. BCL-X expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Res. 1998;58:256-262.
13. Puthier D, Derenne S, Barille S, et al. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol. 1999;107:392-395.
14. Miyake H, Monia BP, Gleave MW. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus Taxol after castration in the Shiongi tumor model. Int J Cancer. 2000;86:855-862.
15. Branch DR, Mills GB. Pp60c-src expression is induced by activation of normal human T lymphocytes. J Immunol. 1995;154:3678-3685.
16. Rowley M, Liu P, Van Ness B. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood. 2000;96:3175-3180.
17. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood. 2001;97:729-736.